Click here to view online. Add this email to your safelist.
Unlocking the future of dyslipidemia care and management
21 August 2025
There is a need for next generation treatment options for dyslipidaemia to address patient population with residual risk despite treatment with statins.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
